761:
Reimer P, Schertlin T, Rüdiger T, Geissinger E, Roth S, Kunzmann V, Weissinger F, Nerl C, Schmitz N, Müller-Hermelink HK, Wilhelm M (2004). "Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first
470:
NK cells are known for their ability to eradicate tumor cells without any prior sensitization to them. One problem when using NK cells in order to fight off lymphoid leukemia is the fact that it is hard to amount enough of them to be effective. One can receive donations of NK cells from parents or
431:
of the cancer when treatment is initiated, and on a composite of numerous risk factors. The median time from diagnosis to death is less than 1 year in patients overall. Patients diagnosed early and/or with fewer risk factors can sometimes enter complete remission and expect much longer survival.
364:(ANKL) is a lymphoid leukemia that is a deficiency NK cells. Not very much is known about this disease due to its rarity, but it is highly aggressive. A majority of patients with NK cell leukemia die within a year of diagnosis, and for ANKL in particular, half of patients die within two months.
466:
Natural killer (NK) cell therapy is used in pediatrics for children with relapsed lymphoid leukemia. These patients normally have a resistance to chemotherapy, therefore, in order to continue on, must receive some kind of therapy. In some cases, NK cell therapy is a choice.
397:. The TCR gene transcripts are normally positive for ANKL. Current Research is attempting to find the causation of ANKL. So far, the researchers have concluded that lineage of the T-cell receptor gene does not predict the behavior of the disease.
1069:
1054:
443:
is a diagnostic tool in order to count/visualize the amount of lymphatic cells in the body. T cells, B cells and NK cells are nearly impossible to distinguish under a microscope, therefore one must use a flow cytometer to distinguish them.
2025:
1769:
457:
Several molecular tumor profiling protocols have been initiated in Europe (e.g., MOSCATO-01, iTHER, and ESMART) to identify actionable lesions for targeted treatment in specific subgroups of patients.
117:
However, the influential WHO Classification (published in 2001) emphasized a greater emphasis on cell lineage. To this end, lymphoid leukemias can also be divided by the type of cells affected:
720:
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camós M, Colomo L, Espinosa I, Martínez S, Ribera JM, Martino R, Gutiérrez-García G, Montserrat E, López-Guillermo A (May 2008).
1323:
560:
Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K (May 2010).
1440:
681:"Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior"
2030:
1000:
Ogbomo, Henry; Cinatl, Jindrich; Mody, Christopher H.; Forsyth, Peter A. (2011). "Immunotherapy in gliomas: Limitations and potential of natural killer (NK) cell therapy".
1839:
722:"Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma"
2053:
1405:
1795:
1134:
900:
Sakamoto, N; Ishikawa, T; Kokura, S; Okayama, T; Oka, K; Ideno, M; Sakai, F; Kato, A; Tanabe, M; Enoki, T; Mineno, J; Naito, Y; Itoh, Y; Yoshikawa, T (2015).
1485:
1998:
2037:
1583:
1328:
1462:
102:
Historically, they have been most commonly divided by the stage of maturation at which the clonal (neoplastic) lymphoid population stopped maturing:
1563:
1361:
471:
relatives through bone marrow transplants. There are also the issues of cost, purity and safety. Unfortunately, there is always the possibility of
1987:
1661:
1215:
295:
216:
1834:
1653:
1204:
540:
236:
1982:
562:"Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type"
211:
Occurs in older adults. Usually involves lymph nodes, bone marrow and spleen. Most patients have peripheral blood involvement. Indolent.
1938:
1558:
1356:
1240:
333:
182:
138:
1829:
1127:
1790:
82:
of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name (for example,
902:"Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer"
2020:
2012:
1871:
1749:
1688:
1674:
1568:
1509:
1346:
1272:
343:
338:
270:
83:
2099:
2068:
1978:
1928:
1824:
1553:
1337:
87:
848:
Rubnitz JE, Inaba H, Kang G, Gan K, Hartford C, Triplett BM, Dallas M, Shook D, Gruber T, Pui CH, Leung W (August 2015).
1960:
1866:
1849:
1657:
1211:
1120:
263:
111:
106:
1901:
1774:
1480:
361:
1816:
1704:
1545:
1467:
644:
Landay AL, Muirhead KA (July 1989). "Procedural guidelines for performing immunophenotyping by flow cytometry".
1906:
1734:
1084:
162:
1372:
298:. It causes 15% of acute leukemias in childhood, and also 40% of lymphomas in childhood. It is most common in
1923:
1474:
233:
with irregular nuclear contours, condensed chromatin, small nucleoli and scant cytoplasm without granules.
1800:
1779:
1693:
197:
196:
Small resting lymphocytes mixed with variable number of large activated cells. Lymph nodes are diffusely
1932:
1522:
1416:
472:
414:
1495:
1318:
131:
1729:
1341:
1252:
418:
1529:
1313:
1283:
1073:
276:
172:
1993:
626:
2094:
1743:
1724:
1713:
1503:
1393:
1308:
1017:
982:
933:
879:
830:
779:
743:
702:
661:
618:
583:
536:
46:
1843:
1622:
1490:
1389:
1112:
1009:
972:
964:
923:
913:
869:
861:
820:
810:
771:
733:
692:
653:
610:
573:
479:
424:
315:
75:
1616:
1611:
1420:
1304:
1170:
1165:
406:
394:
390:
350:
126:
121:
2063:
977:
952:
928:
901:
874:
849:
825:
798:
440:
428:
246:
224:
206:
167:
2088:
1970:
1669:
1578:
1534:
1351:
1225:
657:
410:
287:
T-cell leukemia describes several different types of lymphoid leukemias which affect
202:
1078:
968:
630:
149:
B-cell leukemia describes several different types of lymphoid leukemia which affect
1573:
1235:
815:
1089:
1013:
531:
Mitchell, Richard
Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (2007).
1247:
230:
601:
Oshimi K (July 2003). "Leukemia and lymphoma of natural killer lineage cells".
17:
1143:
918:
697:
680:
299:
71:
55:
1095:
1063:
738:
721:
578:
561:
1021:
986:
937:
883:
834:
783:
775:
747:
706:
622:
587:
478:
NK cell therapy is a possible treatment for many different cancers such as
90:. Most lymphoid leukemias involve a particular subtype of lymphocytes, the
665:
2058:
1886:
1597:
1160:
1147:
417:
are commonly offered as the initial therapy. Some patients may receive a
79:
67:
51:
1046:
614:
865:
799:"T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies"
1606:
1058:
393:(TCR) is an important factor when ANKL is being diagnosed along with
323:
319:
288:
150:
91:
1429:
1294:
1278:
255:
187:
1100:
1892:
1786:
1765:
1683:
1425:
1400:
1380:
1376:
1263:
1181:
1176:
850:"Natural killer cell therapy in children with relapsed leukemia"
349:
In practice, it can be hard to distinguish T-cell leukemia from
240:
1116:
1632:
1627:
1517:
679:
Hong M, Lee T, Young Kang S, Kim SJ, Kim W, Ko YH (May 2016).
311:
307:
1770:
Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma
193:
30% of all leukemias. Also 3 to 4% of lymphomas in adults
372:
The requirements for diagnosing ANKL are as follows:
1036:
2046:
2011:
1969:
1951:
1915:
1885:
1858:
1813:
1758:
1712:
1703:
1643:
1605:
1596:
1544:
1454:
1415:
1371:
1293:
1262:
1224:
1203:
1192:
1159:
1040:
78:. The lymphocytic leukemias are closely related to
45:
37:
32:
1840:Peripheral T-cell lymphoma not otherwise specified
41:Lymphocytic, lymphogenous, lymphoblastic leukemias
1662:Precursor T acute lymphoblastic leukemia/lymphoma
1216:Precursor B acute lymphoblastic leukemia/lymphoma
951:Bachanova, Veronika; Miller, Jeffrey S. (2014).
1406:Nodular lymphocyte predominant Hodgkin lymphoma
555:
553:
525:
523:
521:
519:
517:
515:
302:males. Its morphology is identical to that of
1796:Secondary cutaneous CD30+ large-cell lymphoma
1128:
762:results of a prospective multicenter study".
513:
511:
509:
507:
505:
503:
501:
499:
497:
495:
137:The most common type of lymphoid leukemia is
8:
1486:Post-transplant lymphoproliferative disorder
1441:immunoproliferative immunoglobulin disorders
1999:Diffuse infiltrative lymphocytosis syndrome
382:Germline configuration genes: TCR-β and IgH
2038:Jessner lymphocytic infiltrate of the skin
1709:
1640:
1602:
1584:Primary cutaneous follicle center lymphoma
1329:Primary cutaneous follicle center lymphoma
1200:
1189:
1156:
1135:
1121:
1113:
1037:
159:Comparison of most common B-cell leukemias
29:
976:
927:
917:
873:
824:
814:
737:
696:
577:
1564:Primary cutaneous marginal zone lymphoma
1362:Primary cutaneous marginal zone lymphoma
155:
2026:with bandlike and perivascular patterns
1988:Autoimmune lymphoproliferative syndrome
895:
893:
491:
353:, and they are often grouped together.
304:precursor B-cell lymphoblastic leukemia
296:precursor T-cell lymphoblastic leukemia
217:Precursor B-cell lymphoblastic leukemia
1835:Enteropathy-associated T-cell lymphoma
797:Cordo V, Meijerink J (January 2021).
7:
1983:X-linked lymphoproliferative disease
227:in childhood, Less common in adults
1939:Large granular lymphocytic leukemia
1559:Intravascular large B-cell lymphoma
334:Large granular lymphocytic leukemia
294:The most common T-cell leukemia is
183:B-cell chronic lymphocytic leukemia
139:B-cell chronic lymphocytic leukemia
405:ANKL is treated similarly to most
25:
906:Journal of Translational Medicine
475:while transplanting bone marrow.
1791:CD30+ cutaneous T-cell lymphoma
969:10.1615/CritRevOncog.2014011091
957:Critical Reviews in Oncogenesis
953:"NK Cells in Therapy of Cancer"
322:. It is highly associated with
2021:Cutaneous lymphoid hyperplasia
2013:Cutaneous lymphoid hyperplasia
1872:Adult T-cell leukemia/lymphoma
1750:Adult T-cell leukemia/lymphoma
1689:Anaplastic large-cell lymphoma
1569:Primary cutaneous immunocytoma
1510:Splenic marginal zone lymphoma
344:T-cell prolymphocytic leukemia
339:Adult T-cell leukemia/lymphoma
318:because of involvement of the
271:B-cell prolymphocytic leukemia
84:adult T-cell leukemia/lymphoma
1:
2069:Lymphoproliferative disorders
1979:Lymphoproliferative disorders
1929:Extranodal NK-T-cell lymphoma
1801:Lymphomatoid papulosis type A
1780:Lymphomatoid papulosis type B
1694:Lymphomatoid papulosis type A
1554:Diffuse large B-cell lymphoma
816:10.1158/2643-3230.BCD-20-0093
88:lymphoproliferative disorders
1961:Acute biphenotypic leukaemia
1850:Subcutaneous T-cell lymphoma
1014:10.1016/j.molmed.2011.03.004
1002:Trends in Molecular Medicine
658:10.1016/0090-1229(89)90192-x
306:. Cell markers include TdT,
264:Acute lymphoblastic leukemia
112:Chronic lymphocytic leukemia
107:Acute lymphoblastic leukemia
1902:Aggressive NK-cell leukemia
1775:Pleomorphic T-cell lymphoma
1481:Lymphomatoid granulomatosis
646:Clin. Immunol. Immunopathol
362:Aggressive NK-cell leukemia
2116:
535:. Philadelphia: Saunders.
254:Other types include (with
1155:
919:10.1186/s12967-015-0632-8
698:10.1038/modpathol.2016.47
376:Immature-looking NK cells
314:. It often presents as a
86:). Such diseases are all
2054:Hematological malignancy
1907:Blastic NK cell lymphoma
1735:Granulomatous slack skin
1491:Classic Hodgkin lymphoma
1390:Classic Hodgkin lymphoma
379:Certain immunophenotypes
533:Robbins Basic Pathology
385:Restricted cytotoxicity
220:(ICD-O: 9835/3-9836/3)
803:Blood Cancer Discovery
776:10.1038/sj.thj.6200359
70:affecting circulating
1933:Angiocentric lymphoma
1523:AIDS-related lymphoma
1347:Splenic marginal zone
739:10.1093/annonc/mdn022
579:10.1093/annonc/mdp418
473:Graft vs host disease
415:chemotherapy regimens
329:Other types include:
2100:Lymphocytic leukemia
2031:with nodular pattern
1730:Pagetoid reticulosis
1342:marginal zone B-cell
854:Pediatr Blood Cancer
419:stem cell transplant
266:, mature B-cell type
245:Usually presents as
1530:Helicobacter pylori
1357:Nodal marginal zone
1284:Hairy cell leukemia
1150:and related disease
277:Hairy cell leukemia
2074:Lymphoid leukemias
1994:Leukemoid reaction
1830:Angioimmunoblastic
1496:Burkitt's lymphoma
615:10.1007/bf02983235
64:Lymphoid leukemias
2082:
2081:
2007:
2006:
1947:
1946:
1881:
1880:
1809:
1808:
1725:Mycosis fungoides
1592:
1591:
1450:
1449:
1394:Nodular sclerosis
1309:follicular B cell
1110:
1109:
866:10.1002/pbc.25555
542:978-1-4160-2973-1
252:
251:
61:
60:
33:Lymphoid leukemia
27:Medical condition
16:(Redirected from
2107:
1844:Lennert lymphoma
1710:
1641:
1603:
1468:Primary effusion
1201:
1190:
1157:
1137:
1130:
1123:
1114:
1038:
1026:
1025:
997:
991:
990:
980:
948:
942:
941:
931:
921:
897:
888:
887:
877:
845:
839:
838:
828:
818:
794:
788:
787:
758:
752:
751:
741:
717:
711:
710:
700:
676:
670:
669:
641:
635:
634:
598:
592:
591:
581:
557:
548:
546:
527:
480:Malignant glioma
453:Targeted therapy
425:Overall survival
407:B-cell lymphomas
357:NK cell leukemia
316:mediastinal mass
283:T-cell leukemias
156:
145:B-cell leukemias
132:NK-cell leukemia
76:white blood cell
30:
21:
2115:
2114:
2110:
2109:
2108:
2106:
2105:
2104:
2085:
2084:
2083:
2078:
2042:
2003:
1965:
1953:
1943:
1911:
1890:
1877:
1854:
1815:
1805:
1754:
1699:
1647:
1645:
1620:
1615:
1609:
1588:
1540:
1446:
1423:
1411:
1367:
1305:germinal center
1289:
1258:
1220:
1196:
1194:
1174:
1169:
1163:
1151:
1141:
1111:
1106:
1105:
1049:
1035:
1030:
1029:
999:
998:
994:
963:(1–2): 133–41.
950:
949:
945:
899:
898:
891:
847:
846:
842:
796:
795:
791:
760:
759:
755:
719:
718:
714:
678:
677:
673:
643:
642:
638:
603:Int. J. Hematol
600:
599:
595:
559:
558:
551:
543:
530:
529:Table 12-8 in:
528:
493:
488:
464:
462:NK cell therapy
455:
450:
438:
427:depends on the
403:
395:T-cell leukemia
391:T-cell receptor
370:
359:
351:T-cell lymphoma
285:
225:acute leukemias
219:
185:
147:
127:T-cell leukemia
122:B-cell leukemia
100:
66:are a group of
28:
23:
22:
18:B cell leukemia
15:
12:
11:
5:
2113:
2111:
2103:
2102:
2097:
2087:
2086:
2080:
2079:
2077:
2076:
2071:
2066:
2064:Leukemia cutis
2061:
2056:
2050:
2048:
2044:
2043:
2041:
2040:
2035:
2034:
2033:
2028:
2017:
2015:
2009:
2008:
2005:
2004:
2002:
2001:
1996:
1991:
1985:
1975:
1973:
1967:
1966:
1964:
1963:
1957:
1955:
1949:
1948:
1945:
1944:
1942:
1941:
1936:
1919:
1917:
1913:
1912:
1910:
1909:
1904:
1898:
1896:
1883:
1882:
1879:
1878:
1876:
1875:
1862:
1860:
1856:
1855:
1853:
1852:
1847:
1837:
1832:
1827:
1821:
1819:
1811:
1810:
1807:
1806:
1804:
1803:
1798:
1793:
1783:
1782:
1777:
1772:
1762:
1760:
1756:
1755:
1753:
1752:
1744:Sézary disease
1738:
1737:
1732:
1727:
1718:
1716:
1707:
1701:
1700:
1698:
1697:
1691:
1679:
1678:
1675:Prolymphocytic
1665:
1651:
1649:
1638:
1637:
1636:
1630:
1600:
1594:
1593:
1590:
1589:
1587:
1586:
1581:
1576:
1571:
1566:
1561:
1556:
1550:
1548:
1542:
1541:
1539:
1538:
1526:
1514:
1513:
1512:
1500:
1499:
1498:
1493:
1488:
1483:
1471:
1458:
1456:
1452:
1451:
1448:
1447:
1445:
1444:
1435:
1433:
1413:
1412:
1410:
1409:
1397:
1386:
1384:
1369:
1368:
1366:
1365:
1359:
1354:
1349:
1333:
1332:
1326:
1321:
1316:
1300:
1298:
1291:
1290:
1288:
1287:
1275:
1273:Prolymphocytic
1269:
1267:
1260:
1259:
1257:
1256:
1244:
1231:
1229:
1222:
1221:
1219:
1209:
1207:
1198:
1187:
1186:
1185:
1153:
1152:
1142:
1140:
1139:
1132:
1125:
1117:
1108:
1107:
1104:
1103:
1092:
1081:
1066:
1050:
1045:
1044:
1042:
1041:Classification
1034:
1033:External links
1031:
1028:
1027:
992:
943:
889:
860:(8): 1468–72.
840:
789:
753:
712:
671:
636:
593:
572:(5): 1032–40.
549:
541:
490:
489:
487:
484:
463:
460:
454:
451:
449:
446:
441:Flow cytometry
437:
434:
402:
399:
387:
386:
383:
380:
377:
369:
366:
358:
355:
347:
346:
341:
336:
284:
281:
280:
279:
273:
267:
250:
249:
247:acute leukemia
243:
234:
228:
221:
213:
212:
209:
207:immunoglobulin
200:
194:
191:
179:
178:
175:
170:
168:Histopathology
165:
160:
146:
143:
135:
134:
129:
124:
115:
114:
109:
99:
98:Classification
96:
59:
58:
49:
43:
42:
39:
35:
34:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
2112:
2101:
2098:
2096:
2093:
2092:
2090:
2075:
2072:
2070:
2067:
2065:
2062:
2060:
2057:
2055:
2052:
2051:
2049:
2045:
2039:
2036:
2032:
2029:
2027:
2024:
2023:
2022:
2019:
2018:
2016:
2014:
2010:
2000:
1997:
1995:
1992:
1989:
1986:
1984:
1980:
1977:
1976:
1974:
1972:
1971:Lymphocytosis
1968:
1962:
1959:
1958:
1956:
1950:
1940:
1937:
1934:
1930:
1926:
1925:
1921:
1920:
1918:
1914:
1908:
1905:
1903:
1900:
1899:
1897:
1894:
1888:
1884:
1873:
1869:
1868:
1864:
1863:
1861:
1857:
1851:
1848:
1845:
1841:
1838:
1836:
1833:
1831:
1828:
1826:
1825:Hepatosplenic
1823:
1822:
1820:
1818:
1812:
1802:
1799:
1797:
1794:
1792:
1788:
1785:
1784:
1781:
1778:
1776:
1773:
1771:
1767:
1764:
1763:
1761:
1757:
1751:
1748:
1747:
1746:
1745:
1742:
1736:
1733:
1731:
1728:
1726:
1723:
1720:
1719:
1717:
1715:
1711:
1708:
1706:
1702:
1695:
1692:
1690:
1686:
1685:
1681:
1680:
1676:
1672:
1671:
1670:prolymphocyte
1667:
1666:
1663:
1659:
1655:
1652:
1650:
1642:
1639:
1634:
1631:
1629:
1626:
1625:
1624:
1618:
1613:
1608:
1604:
1601:
1599:
1595:
1585:
1582:
1580:
1579:Plasmacytosis
1577:
1575:
1572:
1570:
1567:
1565:
1562:
1560:
1557:
1555:
1552:
1551:
1549:
1547:
1543:
1536:
1535:MALT lymphoma
1532:
1531:
1527:
1524:
1520:
1519:
1515:
1511:
1508:
1507:
1506:
1505:
1501:
1497:
1494:
1492:
1489:
1487:
1484:
1482:
1479:
1478:
1477:
1476:
1472:
1469:
1465:
1464:
1460:
1459:
1457:
1453:
1443:
1442:
1437:
1436:
1434:
1431:
1427:
1422:
1418:
1414:
1407:
1403:
1402:
1398:
1395:
1391:
1388:
1387:
1385:
1382:
1378:
1374:
1370:
1363:
1360:
1358:
1355:
1353:
1350:
1348:
1344:
1343:
1339:
1338:marginal zone
1335:
1334:
1330:
1327:
1325:
1322:
1320:
1317:
1315:
1311:
1310:
1306:
1302:
1301:
1299:
1296:
1292:
1285:
1281:
1280:
1276:
1274:
1271:
1270:
1268:
1265:
1261:
1254:
1250:
1249:
1245:
1242:
1238:
1237:
1233:
1232:
1230:
1227:
1223:
1217:
1213:
1210:
1208:
1206:
1202:
1199:
1191:
1188:
1183:
1180:
1179:
1178:
1172:
1167:
1162:
1158:
1154:
1149:
1145:
1138:
1133:
1131:
1126:
1124:
1119:
1118:
1115:
1102:
1098:
1097:
1093:
1091:
1087:
1086:
1082:
1080:
1076:
1075:
1071:
1067:
1065:
1061:
1060:
1056:
1052:
1051:
1048:
1043:
1039:
1032:
1023:
1019:
1015:
1011:
1008:(8): 433–41.
1007:
1003:
996:
993:
988:
984:
979:
974:
970:
966:
962:
958:
954:
947:
944:
939:
935:
930:
925:
920:
915:
911:
907:
903:
896:
894:
890:
885:
881:
876:
871:
867:
863:
859:
855:
851:
844:
841:
836:
832:
827:
822:
817:
812:
808:
804:
800:
793:
790:
785:
781:
777:
773:
770:(4): 304–11.
769:
765:
757:
754:
749:
745:
740:
735:
732:(5): 958–63.
731:
727:
723:
716:
713:
708:
704:
699:
694:
691:(5): 430–43.
690:
686:
682:
675:
672:
667:
663:
659:
655:
651:
647:
640:
637:
632:
628:
624:
620:
616:
612:
608:
604:
597:
594:
589:
585:
580:
575:
571:
567:
563:
556:
554:
550:
544:
538:
534:
526:
524:
522:
520:
518:
516:
514:
512:
510:
508:
506:
504:
502:
500:
498:
496:
492:
485:
483:
481:
476:
474:
468:
461:
459:
452:
447:
445:
442:
435:
433:
430:
426:
422:
420:
416:
412:
411:Anthracycline
408:
400:
398:
396:
392:
384:
381:
378:
375:
374:
373:
367:
365:
363:
356:
354:
352:
345:
342:
340:
337:
335:
332:
331:
330:
327:
325:
321:
317:
313:
309:
305:
301:
297:
292:
290:
282:
278:
274:
272:
268:
265:
261:
260:
259:
257:
248:
244:
242:
238:
235:
232:
229:
226:
222:
218:
215:
214:
210:
208:
204:
201:
199:
195:
192:
189:
184:
181:
180:
176:
174:
171:
169:
166:
164:
161:
158:
157:
154:
152:
144:
142:
140:
133:
130:
128:
125:
123:
120:
119:
118:
113:
110:
108:
105:
104:
103:
97:
95:
93:
89:
85:
81:
77:
73:
69:
65:
57:
53:
50:
48:
44:
40:
36:
31:
19:
2073:
1922:
1865:
1859:By infection
1740:
1739:
1721:
1682:
1668:
1646:development/
1574:Plasmacytoma
1528:
1516:
1502:
1473:
1461:
1455:By infection
1438:
1399:
1336:
1303:
1277:
1246:
1236:naive B cell
1234:
1195:development/
1094:
1083:
1068:
1053:
1005:
1001:
995:
960:
956:
946:
909:
905:
857:
853:
843:
809:(1): 19–31.
806:
802:
792:
767:
763:
756:
729:
725:
715:
688:
684:
674:
652:(1): 48–60.
649:
645:
639:
609:(1): 18–23.
606:
602:
596:
569:
565:
547:8th edition.
532:
477:
469:
465:
456:
439:
423:
413:-containing
404:
388:
371:
360:
348:
328:
303:
293:
286:
253:
231:Lymphoblasts
173:Cell markers
148:
136:
116:
101:
74:, a type of
63:
62:
1741:aggressive:
1714:MF+variants
1253:Mantle cell
1248:mantle zone
685:Mod. Pathol
326:mutations.
72:lymphocytes
38:Other names
2089:Categories
1817:peripheral
1314:Follicular
1144:Leukaemias
764:Hematol. J
726:Ann. Oncol
566:Ann. Oncol
486:References
300:adolescent
205:, surface
190:: 9823/3)
56:hematology
1952:Lymphoid+
1722:indolent:
1705:Cutaneous
1546:Cutaneous
1324:GCB DLBCL
1319:Burkitt's
1148:lymphomas
1096:SNOMED CT
448:Treatment
436:Diagnosis
401:Treatment
368:Diagnosis
275:9940/3 –
269:9833/3 –
262:9826/3 –
177:Comments
163:Incidence
80:lymphomas
68:leukemias
47:Specialty
2095:Leukemia
2059:leukemia
1617:leukemia
1612:lymphoma
1171:leukemia
1166:lymphoma
1101:32280000
1022:21507717
987:24941379
938:26303618
884:25925135
835:34661151
784:15297846
748:18303032
707:27015135
631:24785150
623:12894846
588:19850638
52:Oncology
2047:General
1954:myeloid
1916:T or NK
1887:NK cell
1241:CLL/SLL
1090:D007945
978:4066212
929:4548900
912:: 277.
875:4634362
826:8447273
666:2656019
289:T cells
258:code):
223:85% of
198:effaced
151:B cells
92:B cells
1891:(most
1867:HTLV-1
1759:Non-MF
1648:marker
1621:(most
1607:T cell
1279:CD11c+
1197:marker
1175:(most
1161:B cell
1020:
985:
975:
936:
926:
882:
872:
833:
823:
782:
746:
705:
664:
629:
621:
586:
539:
324:NOTCH1
320:thymus
1814:Other
1684:CD30+
1430:CD138
1401:CD20+
1295:CD79a
627:S2CID
429:stage
256:ICD-O
188:ICD-O
1893:CD56
1787:CD30
1766:CD30
1654:TdT+
1598:T/NK
1463:KSHV
1439:see
1426:CD38
1417:PCDs
1381:CD30
1377:CD15
1352:MALT
1264:CD22
1205:TdT+
1182:CD20
1177:CD19
1085:MeSH
1074:9-CM
1018:PMID
983:PMID
934:PMID
880:PMID
831:PMID
780:PMID
744:PMID
703:PMID
662:PMID
619:PMID
584:PMID
537:ISBN
389:The
241:CD19
1924:EBV
1789:+:
1768:-:
1658:ALL
1633:CD8
1628:CD4
1623:CD3
1518:HIV
1504:HCV
1475:EBV
1379:+,
1226:CD5
1212:ALL
1079:204
1070:ICD
1064:C91
1055:ICD
1010:doi
973:PMC
965:doi
924:PMC
914:doi
870:PMC
862:doi
821:PMC
811:doi
772:doi
734:doi
693:doi
654:doi
611:doi
574:doi
421:.
312:CD7
308:CD2
237:TdT
203:CD5
2091::
1656::
1644:By
1432:+)
1428:+/
1421:PP
1383:+)
1373:RS
1193:By
1146:,
1099::
1088::
1077::
1062::
1059:10
1016:.
1006:17
1004:.
981:.
971:.
961:19
959:.
955:.
932:.
922:.
910:13
908:.
904:.
892:^
878:.
868:.
858:62
856:.
852:.
829:.
819:.
805:.
801:.
778:.
766:.
742:.
730:19
728:.
724:.
701:.
689:29
687:.
683:.
660:.
650:52
648:.
625:.
617:.
607:78
605:.
582:.
570:21
568:.
564:.
552:^
494:^
482:.
409:.
310:,
291:.
239:,
153:.
141:.
94:.
54:,
1990:)
1981:(
1935:)
1931:/
1927:(
1895:)
1889:/
1874:)
1870:(
1846:)
1842:(
1696:)
1687:(
1677:)
1673:(
1664:)
1660:(
1635:)
1619:)
1614:,
1610:(
1537:)
1533:(
1525:)
1521:(
1470:)
1466:(
1424:(
1419:/
1408:)
1404:(
1396:)
1392:(
1375:(
1364:)
1345:(
1340:/
1331:)
1312:(
1307:/
1297:+
1286:)
1282:(
1266:+
1255:)
1251:(
1243:)
1239:(
1228:+
1218:)
1214:(
1184:)
1173:)
1168:,
1164:(
1136:e
1129:t
1122:v
1072:-
1057:-
1047:D
1024:.
1012::
989:.
967::
940:.
916::
886:.
864::
837:.
813::
807:2
786:.
774::
768:5
750:.
736::
709:.
695::
668:.
656::
633:.
613::
590:.
576::
545:.
186:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.